Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Telomelysin Submission Likely Delayed into 2024 or Later: Oncolys/Chugai
Chugai Pharmaceutical is anticipating a delay in its Japanese regulatory submission for telomelysin, an oncolytic virus licensed from Tokyo-based biotech Oncolys BioPharma, for the treatment of esophageal cancer, due to COVID-19. Oncolys said on April 14 that it has been…
To read the full story
Related Article
- Drug Pricing to Be Applied to Oncolys Oncolytic Virus Therapy
June 25, 2026
- Oncolys Targets 300 Hospitals for Telomelysin Rollout
June 9, 2026
- Oncolys Aims for First-Line Use of Telomelysin in Esophageal Cancer
January 19, 2026
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Oncolys Seeks Marketing License for Regenerative Medicine in Japan
November 27, 2024
- Oncolys Forms Oncolytic Virus Sales Collab with Fujifilm in Japan
February 8, 2024
- Telomelysin-Radiation Combo Hits Mark in PII Esophageal Cancer Study: Oncolys
October 17, 2023
- Oncolys Keeps 2024 Target for Japan Telomelysin Filing; Partner Talks Ongoing
December 20, 2022
- 2024 Japan Filing Plan for Oncolytic Virus Unchanged: Oncolys President
August 8, 2022
- Oncolys to Receive 500 Million Yen from Chugai in Telomelysin Milestone
December 13, 2019
- Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
April 9, 2019
BUSINESS
- Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 25, 2026
- EU Approves Padcev-Keytruda for Earlier Bladder Cancer Use
June 25, 2026
- Regenxbio Clears Path to Resubmit Hunter Syndrome Gene Therapy
June 24, 2026
- Merck Biopharma Files Lurbinectedin for SCLC in Japan
June 24, 2026
- FRONTEO Joins Dementia Prevention Cohort Study with KIBIT AI
June 24, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…